Chiou C C, Groll A H, Walsh T J
National Cancer Institute, Bethesda, Maryland, USA.
Oncologist. 2000;5(2):120-35. doi: 10.1634/theoncologist.5-2-120.
Invasive fungal infections have emerged as important causes of morbidity and mortality in profoundly immunocompromised patients with cancer. Current treatment strategies for these infections are limited by antifungal resistance, toxicity, drug interactions, and expense. In order to overcome these limitations, new antifungal compounds are being developed, which may improve our therapeutic armamentarium for prevention and treatment of invasive mycoses in high-risk patients with neoplastic diseases.
侵袭性真菌感染已成为癌症深度免疫受损患者发病和死亡的重要原因。目前针对这些感染的治疗策略受到抗真菌耐药性、毒性、药物相互作用和费用的限制。为了克服这些限制，正在开发新的抗真菌化合物，这可能会改善我们用于预防和治疗肿瘤性疾病高风险患者侵袭性真菌病的治疗手段。
